@article{2ccf282e-1b2e-4efa-8d5e-357784538e1e,
  abstract     = {{<p>Beta-amyloid positron emission tomography/computed tomography (PET/CT) with [<sup>18</sup>F]flutemetamol is used to demonstrate presence of Alzheimer’s disease. With the possibility to use [<sup>18</sup>F]flutemetamol PET/CT for early detection of mild cognitive impairment and the development of prevention drugs, the demand for the procedure may increase significantly. The biokinetics and dosimetry of [<sup>18</sup>F]flutemetamol in 7 patients (62–73 y) were studied. Knee-to-head PET/CT scans were acquired 15 min, 1, 2, 3, 4, and 5 hours after intravenous injection of 185 MBq. Activity in blood samples and 20-hour urine was analyzed. Volumes of interest for organs with enhanced activity content were segmented in the PET-images. A biokinetic compartment model was created to derive time-activity data for different organs. Organ doses and effective dose were calculated using IDAC-Dose 2.1 in accordance with ICRP publication 103. The effective dose coefficient for [<sup>18</sup>F]flutemetamol was 21 μSv/MBq (4 mSv@185 MBq). The colon received highest absorbed dose, 17 mGy.</p>}},
  author       = {{Leide-Svegborn, Sigrid and Minarik, David and Solem, Rasmus and Hägerström, Douglas and Andersson, Martin}},
  issn         = {{0144-8420}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{3-4}},
  pages        = {{130--139}},
  publisher    = {{Oxford University Press}},
  series       = {{Radiation Protection Dosimetry}},
  title        = {{Biokinetics and dosimetry of [<sup>18</sup>F]flutemetamol in patients with Alzheimer’s disease}},
  url          = {{http://dx.doi.org/10.1093/rpd/ncaf165}},
  doi          = {{10.1093/rpd/ncaf165}},
  volume       = {{202}},
  year         = {{2026}},
}